Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

Detalles Bibliográficos
Autores principales: Eşkazan, Ahmet Emre, Soysal, Teoman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2013
Materias:
Letter to Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878458/
https://www.ncbi.nlm.nih.gov/pubmed/24385789
http://dx.doi.org/10.4274/Tjh.2012.0013
_version_ 1782297808299098112
author Eşkazan, Ahmet Emre
Soysal, Teoman
author_facet Eşkazan, Ahmet Emre
Soysal, Teoman
author_sort Eşkazan, Ahmet Emre
collection PubMed
description
format Online
Article
Text
id pubmed-3878458
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-38784582014-01-02 Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia Eşkazan, Ahmet Emre Soysal, Teoman Turk J Haematol Letter to Editor Galenos Publishing 2013-06 2013-06-05 /pmc/articles/PMC3878458/ /pubmed/24385789 http://dx.doi.org/10.4274/Tjh.2012.0013 Text en © Turkish Journal of Hematology, Published by Galenos Publishing. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to Editor
Eşkazan, Ahmet Emre
Soysal, Teoman
Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
title Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
title_full Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
title_fullStr Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
title_full_unstemmed Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
title_short Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
title_sort dasatinib may override f317l bcr-abl kinase domain mutation in patients with chronic myeloid leukemia
topic Letter to Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878458/
https://www.ncbi.nlm.nih.gov/pubmed/24385789
http://dx.doi.org/10.4274/Tjh.2012.0013
work_keys_str_mv AT eskazanahmetemre dasatinibmayoverridef317lbcrablkinasedomainmutationinpatientswithchronicmyeloidleukemia
AT soysalteoman dasatinibmayoverridef317lbcrablkinasedomainmutationinpatientswithchronicmyeloidleukemia

Ejemplares similares